According to the targeted sequencing data of 1660 cancer patients, ARID1A (12%), ARID1B (5%), ARID2 (6%) and ARID5B (2.6%) mutations are prevalent mutations in this family, as shown in Figure 1(a). Here, ARID2 is linked to cancer.